MARKET

BHVN

BHVN

Biohaven
NYSE
11.09
-0.03
-0.27%
After Hours: 11.09 0 0.00% 16:47 06/09 EDT
OPEN
11.24
PREV CLOSE
11.12
HIGH
12.00
LOW
10.68
VOLUME
3.77M
TURNOVER
--
52 WEEK HIGH
18.57
52 WEEK LOW
7.48
MARKET CAP
1.67B
P/E (TTM)
-1.9564
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BHVN last week (0601-0605)?
Weekly Report · 1d ago
Acting FDA head vows to block political interference, Endpoint News says
TipRanks · 5d ago
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations
Seeking Alpha · 06/02 14:20
FDA issues draft guidance to help accelerated cell, gene therapies for patients
TipRanks · 06/02 14:03
Weekly Report: what happened at BHVN last week (0525-0529)?
Weekly Report · 06/01 10:08
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX)
TipRanks · 05/30 14:30
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), AngioDynamics (ANGO)
TipRanks · 05/29 13:31
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN) and Healthequity (HQY)
TipRanks · 05/29 10:11
More
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; Molecular Degrader of Extracellular Proteins (MoDE) and Targeted Removal of Aberrant Protein (TRAP) extracellular protein degradation for immunological diseases; and myostatin-activin pathway targeting agent for neuromuscular and metabolic diseases, including obesity. Its pipeline includes TYK2/JAK1 Inhibitor (brain-penetrant), IgG Degrader, Gd-IgA1 TRAP Degrader, Taldefgrobep Alfa, Kv7 Activator, TRPM3 Antagonist FGFR3 ADC, CD30 ADC, Trop2 ADC +/- PD1, and others. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Webull offers Biohaven Ltd stock information, including NYSE: BHVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BHVN stock methods without spending real money on the virtual paper trading platform.